

Atonal homolog 7 (ATOH7) loss-of-function mutations in predominant bilateral optic nerve hypoplasia

Journal Article**Author(s):**

Atac, David; Koller, Samuel; Hanson, James V.M.; Feil, Silke; Tiwari, Amit; Bahr, Angela; Baehr, Luzy; Magyar, István; Kottke, Raimund; Gerth-Kahlert, Christina; Berger, Wolfgang

Publication date:

2020-01-01

Permanent link:

<https://doi.org/10.3929/ethz-b-000399327>

Rights / license:

In Copyright - Non-Commercial Use Permitted

Originally published in:

Human Molecular Genetics 29(1), <https://doi.org/10.1093/hmg/ddz268>

GENERAL ARTICLE

Atonal homolog 7 (ATOH7) loss-of-function mutations in predominant bilateral optic nerve hypoplasia

David Atac^{1,†}, Samuel Koller¹, James V.M. Hanson², Silke Feil¹, Amit Tiwari¹, Angela Bahr¹, Luzy Baehr¹, István Magyar¹, Raimund Kottke³, Christina Gerth-Kahlert² and Wolfgang Berger^{1,4,5,*}

¹Institute of Medical Molecular Genetics, University of Zurich, Schlieren 8952, Switzerland, ²Department of Ophthalmology, University Hospital Zurich and University of Zurich, Zurich 8091, Switzerland, ³Department of Diagnostic Imaging, University Children's Hospital Zurich, Zurich 8032, Switzerland, ⁴Zurich Center for Integrative Human Physiology, University of Zurich, Zurich 8057, Switzerland and ⁵Neuroscience Center Zurich, University and ETH Zurich, Zurich 8057, Switzerland

*To whom correspondence should be addressed. Tel: +41 445563350; Fax: + 41 445563351; Email: berger@medmolgen.uzh.ch

Abstract

Optic nerve hypoplasia (ONH) is a congenital optic nerve abnormality caused by underdevelopment of retinal ganglion cells (RGCs). Despite being a rare disease, ONH is the most common optic disk anomaly in ophthalmological practice. So far, mutations in several genes have been identified as causative; however, many cases of ONH remain without a molecular explanation. The early transcription factor atonal basic-helix-loop-helix (bHLH) transcription factor 7 (ATOH7) is expressed in retinal progenitor cells and has a crucial role in RGC development. Previous studies have identified several mutations in the ATOH7 locus in cases of eye developmental diseases such as non-syndromic congenital retinal non-attachment and persistent hyperplasia of the primary vitreous. Here we present two siblings with a phenotype predominated by bilateral ONH, with additional features of foveal hypoplasia and distinct vascular abnormalities, where whole-exome sequencing identified two compound heterozygous missense mutations affecting a conserved amino acid residue within the bHLH domain of ATOH7 (NM_145178.3:c.175G>A; p.(Ala59Thr) and c.176C>T; p.(Ala59Val)). ATOH7 expression constructs with patient single nucleotide variants were cloned for functional characterization. Protein analyses revealed decreased protein amounts and significantly enhanced degradation in the presence of E47, a putative bHLH dimerization partner. Protein interaction assays revealed decreased heterodimerization and DNA-binding of ATOH7 variants, resulting in total loss of transcriptional activation of luciferase reporter gene expression. These findings strongly support pathogenicity of the two ATOH7 mutations, one of which is novel. Additionally, this report highlights the possible impact of altered ATOH7 dimerization on protein stability and function.

Introduction

Congenital visual impairment can be caused by optic nerve hypoplasia [ONH; online Mendelian inheritance in man (OMIM) #165550], which has been recognized as one of the most common

causes of childhood blindness with a prevalence of 2.4–17.3 cases per 100 000 (1–3). ONH is the most common and severe type of congenital optic nerve anomaly, characterized by small, normal,

[†]David Atac, <http://orcid.org/0000-0001-6537-8627>

Received: August 27, 2019. Revised: October 23, 2019. Accepted: October 25, 2019

grey or pale-appearing optic nerves with a typical 'double-ring sign' on funduscopy associated with abnormalities in size and distribution of the retinal vessels (4). It is estimated that approximately 80% of patients suffering from bilateral ONH are legally blind; however, the phenotype is highly variable and ranges from nearly normal vision to no perception of light (5). Although ONH does occur as an isolated trait, most cases are associated with developmental abnormalities such as anterior segmental defects of the eye, septo-optic dysplasia, hemispheric or pituitary abnormalities, developmental delay and autism spectrum disorders (4,6–8).

ONH typically presents as sporadic cases, many of which remain without a clear molecular diagnosis. With advances in high-throughput sequencing technology over the past decade, several ONH-associated mutations have been reported, a majority of which occur in neural or retinal transcription factor genes (9). Homeobox expressed in embryonic stem cells 1 (HESX1) mutations have been identified as a rare cause of ONH with septo-optic dysplasia and hypopituitarism, but also documented in patients without ONH (10–13). Paired box 6 (PAX6) mutations were described in patients with bilateral ONH as well as patients with unilateral or bilateral optic nerve aplasia (ONA) (6). Sex-determining region Y box 2 (SOX2) mutations were found in several patients suffering from ONH and either brain malformations or microphthalmia/anophthalmia (8). Heterozygous nuclear receptor subfamily 2 group F member 1 (NR2F1) mutations have been detected in several patients suffering from Bosch-Boonstra-Schaaf Optic Atrophy Syndrome, which includes ONH (14). Heterozygous mutations in orthodenticle homeobox 2 (OTX2) are the second most common cause for microphthalmia/anophthalmia and approximately a third of these patients have ONH (15,16). A homozygous missense variant in ventral anterior homeobox 1 (VAX1) has also been reported in a patient with microphthalmia, ONH and brain malformations (17).

Atonal basic-helix-loop-helix (bHLH) transcription factor 7 (ATOH7) encodes a 152 amino acid protein, which forms a helix-loop-helix (HLH) domain responsible for protein dimerization as well as a DNA-binding basic domain located within the first helix (18). The mouse ortholog mouse atonal homolog 5 (*Math5*) has been identified as a crucial factor in the development of the retina, specifying the differentiation of retinal ganglion cells (RGCs) from retinal progenitor cells (19). *Math5*^{-/-} mice display normal sized eyes without optic nerves, chiasmata or RGCs but with an increased number of cone photoreceptors (20). Transgene expression of *ATOH7* in human-induced pluripotent stem cells (hiPSCs) has been likewise demonstrated to drive differentiation of RGCs (21). Several single nucleotide polymorphisms (SNPs) in the 5'-untranslated region (UTR) of *ATOH7* were found to be associated with optic disk size in a genome-wide association study (22).

ATOH7 is implicated in several developmental eye disorders. Mutations in a remote upstream transcription enhancer region of *ATOH7* were associated with non-syndromic congenital retinal non-attachment (NCRNA; OMIM #221900) (23,24). A missense point-mutation in the DNA-binding domain of *ATOH7* (p.(Asn46His)) was shown to lead to persistent hyperplasia of the primary vitreous (OMIM #221900) (25). This replicates a previous finding in *Math5*^{-/-} mice, in which lack of RGCs resulted in abnormal retinal vessel development and persistent hyaloid vasculature (20). A homozygous frameshift mutation in the *ATOH7* coding region has been identified in two Turkish siblings suffering from various developmental eye defects

including, among others, microphthalmia, persistent fetal vasculature (PFV; OMIM #221900), ONH and NCRNA (26). Khan *et al.* also described a severe phenotype in several affected members of a consanguineous family from Pakistan caused by a homozygous *ATOH7* missense mutation (p.(Glu49Val)). The phenotype involved microcornea, microphthalmia, dense corneal opacities, retrolental mass and severe retinal and vitreous dysplasia.

Although a potential link to ONH is implied by its occurrence as part of various global eye phenotypes caused by *ATOH7* mutations, the role of this transcription factor in ONH remains unclarified. In a study including 34 ONH patients with or without septo-optic dysplasia, six sequence variants were identified within the UTR of the *ATOH7* locus as well as one intronic variant (27), but no mutations in the coding region. In another study, Sanger sequencing of 12 patients suffering from ONH or ONA identified two heterozygous missense variants p.(Ala47Thr) and p.(Arg65Gly) in *ATOH7* (22). However, *in vitro* functional characterization could not confirm these variants as causative of the phenotype (25).

Here we present two compound heterozygous missense mutations in *ATOH7*, NM_145178.3:c.175G>A (p.(Ala59Thr)) and c.176C>T (p.(Ala59Val)), which segregate with an ocular phenotype dominated by bilateral ONH in a Swiss family with two affected siblings. Glial tissue was present in one of the patients. This may be interpreted as a variant of PFV. Findings of abnormal retinal vasculature, including tortuosity and incomplete peripheral vascularization (the far peripheral retina could only be examined in one patient), were present upon examination and may be an indirect result of the interruption of RGC development by the described *ATOH7* mutations. As Provis pointed out, the primary retinal vasculature develops at the retinal nerve fiber layer (RNFL)/RGC interface (28). Thus, a disturbance of this interface will interrupt retinal vessel development. This is evidenced clinically by the frequent association of optic disk anomalies with abnormal retinal vessel distribution.

Additionally, foveal hypoplasia (FVH) was present in the affected siblings as well as the father. A heterozygous missense single nucleotide variant (SNV) in optic atrophy 3 (*OPA3*), NM_001017989.2:c.43G>C (p.Gly15Arg), was found in all family members presenting with FVH and was proposed as an additional potential candidate for this finding. A detailed *in vitro* functional assessment of the respective mutant *ATOH7* proteins expressed in human embryonic kidney cell 293 T (HEK293T) cells was performed, addressing protein expression, stability and function. As bHLH transcription factors primarily act as heterodimers with other bHLH proteins, the bHLH transcription factor E2-alpha isoform E47 (E47), encoded by the transcription factor 3 (*TCF3*) gene (29), was co-expressed as a putative binding partner in functional assays. Our findings indicate that the patient-derived *ATOH7* sequence variants (p.(Ala59Thr) and p.(Ala59Val)), which affect a highly conserved amino acid residue within the HLH domain, have a significant impact on protein stability, heterodimerization and DNA-binding, as well as a total loss of *ATOH7*-induced transcriptional activation. The presented ONH cases are the first report of compound heterozygous *ATOH7* missense mutations associated with a non-syndromic ocular phenotype dominated by ONH. Furthermore, this report highlights the impact of *ATOH7* protein dimerization on protein stability and function. In the light of these observations, analysis of *ATOH7* in patients with isolated and sporadic ONH is highly recommended.

Results

Severe bilateral ONH and FVH in two siblings with poor vision

The index patient was referred to the Department of Ophthalmology at the University Hospital of Zurich at the age of seven years due to unexplained low vision despite corrective glasses and amblyopia treatment. The patient had a history of esotropia observed at the age of two-and-a-half years and myopic astigmatism observed at the age of four years. No extraocular manifestations were present. The index patient's younger sister was referred at the age of three due to reduced visual function. The patient had a history of esotropia at the age of two years. The two older siblings and the non-consanguineous parents of Caucasian ancestry had no history of visual disabilities. The affected children had no history of prematurity, were cognitively normal for their age and had excellent grades at school during the observation period.

Initial examination of the index patient revealed best-corrected visual acuity at distance 20/100 right eye (RE) and 20/200 left eye (LE) and at near 20/80 (RE) and 20/100 (LE) at age seven years. Left microesotropia was present. Refraction showed myopic astigmatism. Examination of the younger affected sibling revealed that visual acuity at near was reduced to 20/200 (RE) and 20/100 (LE) at three years of age. Orthoptic assessment diagnosed a right microesotropia with eccentric fixation superior to the presumed foveola. Refraction showed hyperopic astigmatism. Neurological and endocrinological assessment was normal in both siblings. Visual acuity was stable during the observation period up to age 11 and 6 in the index patient and her sister, respectively. The remaining family members had a normal visual function and optic nerve development.

Dilated fundus examination of the index patient and her younger sister demonstrated bilateral severe ONH as well as signs of FVH and abnormal vessel distribution with tortuosity and drag of the retinal vessels towards the temporal side (Fig. 1A–B). Imaging of the peripheral retina revealed incomplete vascularization of the far peripheral retina, without visible signs of neovascularization, in the affected sibling (unfortunately the index patient was not available for further imaging) (Supplementary Material, Fig. S1); for this reason, as well as the ages of the patients, no angiography was performed. There was no sign of microphthalmia or microcornea. Optical coherence tomography (OCT) revealed significantly reduced thickness of the RNFL as well as the ganglion cell and inner plexiform layers (GC IPL) in the two affected siblings (Table 1). The index patient and her father showed also signs of grade 1 FVH with absent extrusion of plexiform layers and a shallow foveal pit (Fig. 1G and C, respectively), whereas the affected sibling showed grade 2 hypoplasia with absent extrusion of plexiform layers and absent foveal pit (Fig. 1H). Structural grading of foveal morphology was performed according to Thomas *et al.* (30). The other family members exhibited normal OCT findings of the optic nerve and macular region (Table 1; Fig. 1D–F).

Cerebral magnetic resonance imaging (MRI) of the index patient confirmed severely hypoplastic optic nerves within small optic nerve sheaths (Fig. 1I and J) in comparison to a control (Fig. 1K and L). No abnormalities of midline structures or other brain areas were observed. No MRI was performed on the affected younger sibling because of the similarity between her fundus changes and those of her sister and her normal developmental state and because successful MRI scan acquisition would have required sedation due to her age.

Compound heterozygous ATOH7 missense variants segregate with ONH

Whole exome sequencing (WES) of the index patient and the affected sister revealed two biallelic missense variants in the bHLH domain of ATOH7: NM_145178.3:c.175G>A; p.(Ala59Thr) and c.176C>T; p.(Ala59Val), of which p.(Ala59Thr) is not present in genome databases and p.(Ala59Val) is a rare variant with a minor allele frequency (MAF) of one in 25 000 in non-Finnish European (NFE) population. No other rare variants were detected in a gene panel consisting of a total of 29 genes (Supplementary Material, Table S1) previously associated with ONH (8,10,14,16,17,26,31–46) and/or FVH (40,47–51).

The discovered ATOH7 variants segregated with ONH within the family (Fig. 2A). Sanger sequencing confirmed compound heterozygosity in the affected siblings and the presence of heterozygous variants in the unaffected family members (Fig. 2B). The unaffected parents as well as the two unaffected siblings were all carriers of either of the two variants. Both variants were predicted likely to be disease-causing by three different algorithms (Table 2), affecting a highly conserved amino acid residue within the first helix of the bHLH domain of ATOH7 (Supplementary Material, Fig. S2). High-throughput sequencing of a 9.3 kb long-range polymerase chain reaction (PCR) product spanning the entire ATOH7 locus was performed on all family members and excluded additional rare sequence variants, in introns as well as in flanking regions.

Genetic testing for FVH in the father

The father of the two affected siblings revealed FVH upon OCT examination. This was also seen in the two affected siblings. In order to investigate whether there was an independent genetic reason for this finding in the father, we performed WES. As no additional rare variants were found in candidate genes associated with ONH and/or FVH (Supplementary Material, Table S1), the gene list was extended to include our institute's gene panel for eye diseases (<https://www.medmolgen.uzh.ch/de/services/Hauptgene.html>; accessed 01.07.2019). The extended filtering revealed a rare heterozygous OPA3 exon 1 sequence variation, with a MAF of one in 100 000 in the NFE population, which was discovered in the father (NM_001017989.2:c.43G>C; p.(Gly15Arg)) and was also present in the affected siblings. Sanger sequencing of this OPA3 variant revealed that the unaffected older sister was also a carrier (Supplementary Material, Fig. S3). The OPA3 variant was predicted likely to be disease-causing by three different algorithms (Table 2). However, since it is also present in the unaffected sister, it may not be the causative sequence variant for the clinical feature of FVH in this family. Alternatively, incomplete penetrance may explain the unaffected mutation carrier.

Reduced protein amounts of ATOH7 variants in the presence of a dimerization partner

Protein amounts of transgenic V5-tagged ATOH7 in HEK293T cells were measured by semi-quantitative western blot (Fig. 3 and Supplementary Material, Fig. S4). To simulate heterozygosity, both patient-derived variants were co-expressed with wild type ATOH7. The previously characterized ATOH7 mutation p.(Asn46His) was included in the experiments as a loss-of-function control (25). As an additional control, an artificial




Figure 1. (A and B) Color fundus images showing a small and dysplastic optic disk and FVH associated with abnormal retinal vasculature in both eyes of index patient (A) and the affected sibling (B), together with pre-retinal gliotic tissue (B). Upper images are centered on the optic nerve; lower images are centered on the fovea; left images represent the RE; right images represent the LE. (C–H) OCT images centered on the fovea show a shallow foveal pit and continuity in all retinal layers in the father (C) and the index patient (G), while the affected sister (H) shows absence of the foveal pit and continuity in all cell layers. The unaffected mother (D) and the older brother (E) and sister (F) show normal OCT findings. (I–J) Coronal T2w fat-saturated images of patient showing severely hypoplastic optic nerves (arrows) with adjacent bright fluid signal within small optic nerve sheaths (I) and small optic nerves in the suprasellar cistern (arrows in J). The optic chiasm was not visualized. (K–L) MRI findings in a healthy five-year-old boy (imaged following facial trauma) are presented for comparison, showing normal size of the optic nerves, optic nerve sheaths and optic chiasm (arrows in K and L).

missense variant (NM_145178.3:c.176C>G; p.(Ala59Gly)) was constructed, with high biochemical similarity of the substituted amino acid residue to its wild type counterpart.

No statistically significant difference in variant protein amount was detected in comparison to wild type ATOH7 (Fig. 3A). The bHLH E47, encoded by TCF3, represents a putative dimerization partner of ATOH7 (25). In the presence of co-expressed E47, a significant decrease in protein amounts of patient variants was observed relative to wild type ATOH7,

suggesting reduced protein stability of ATOH7 when forming heterodimers with E47 (Fig. 3B). Reduced amounts were observed to a lesser degree for the artificial variant, the loss-of-function control p.(Asn46His), as well as for the patient variants co-expressed with wild type ATOH7. Treatment with proteasome inhibitor MG-132 completely restored the relative ATOH7 variant protein amounts (except for p.(Ala59Val)) when co-expressed with E47 (Fig. 3D), suggesting proteasome-dependent degradation.

Table 1. OCT measurements in family members

Patient	Age at examination (years)	Eye	TMV	CRT	GCIPL	RNFL	ONH diameter	FVH
71877 (mother)	51	RE	8.64	243	0.79	87	1589 × 1883	NA
		LE	8.62	241	0.8	90	1505 × 1709	NA
71965 (father)	49	RE	9.32	300	0.85	104	1589 × 1754	1°
		LE	9.34	302	0.84	104	1635 × 1819	1°
72447 (sister)	18	RE	9.84	229	0.86	104	1570 × 1731	NA
		LE	9.68	230	0.87	105	1523 × 1674	NA
72484 (brother)	14	RE	9.32	232	0.83	123	1700 × 1623	NA
		LE	9.31	232	0.85	124	1613 × 1786	NA
72005 (index patient)	11	RE	NA	NA	NA	NA	NA	NA
		LE	7.53	284	NA	NA	(hypoplasia)	1°
71953 (affected sibling)	7	RE	7.28	278	0.33	28	(hypoplasia)	2°
		LE	NA	NA	NA	NA	(hypoplasia)	NA

CRT, central macular thickness; NA, not available; ONH, optic nerve head; RNFL, retinal nerve fiber layer thickness. GCIPL volume is quantified in mm³ over the 1, 2, 22, 3.45 mm ETDRS grid; TMV is quantified in mm³ over the 1, 3, 6 mm ETDRS grid. RNFL is quantified as the average (global) thickness over 360° in μm. Gray shading: significantly reduced; black shading: thicker than normal. FVH is graded according to the system proposed by Thomas et al. (30).

Table 2. Described sequence variations and predicted impact on function

RefSeq	cDNA variation	AA variation	MAF (NFE)	SIFT	MutationTaster2	PolyPhen2
NM_145178.3(ATOH7)	c.175G>A	p.(Ala59Thr)	None	Deleterious (score: 0.00)	Disease-causing (P-value: 1)	Probably-damaging (score: 1.00)
NM_145178.3(ATOH7)	c.176C>T	p.(Ala59Val)	4 × 10 ⁻⁵	Deleterious (score: 0.00)	Disease-causing (P-value: 1)	Probably-damaging (score: 1.00)
NM_001017989.2(OPA3)	c.43G>C	p.(Gly15Arg)	1 × 10 ⁻⁵	Deleterious (score: 0.01)	Disease-causing (P-value: 1)	Probably-damaging (score: 1.00)

AA, amino acid; MAF, minor allele frequency (GnomAD).

Co-expression of E47 increases proteasome-mediated degradation of variant ATOH7 protein

Cycloheximide (CHX) time course assays were performed in order to verify the suggested increased protein turnover of ATOH7 variants (Fig. 4 and Supplementary Material, Fig. S5). HEK293T expressing V5-tagged ATOH7 were pretreated with CHX to block protein synthesis, and protein amounts were quantified by western blot at time points 0–4 h post CHX addition. No significant difference in protein stability was observed for any of the ATOH7 variants in the absence of the putative dimerization partner E47 (Fig. 4A), while co-expression of E47 significantly increased the turnover rate of the ATOH7 patient variants. The loss-of-function variant p.(Asn46His) and the synthetic variant p.(Ala59Gly) demonstrated similar turnover rates, which were significantly increased compared to wild type ATOH7 but significantly slower compared to ATOH7 patient variants (Fig. 4B). Treatment with MG-132, an inhibitor of proteasomal degradation, resulted in normalization of all protein variant turnover rates relative to wild type ATOH7. This confirmed proteasome-mediated degradation as the main mechanism for reduced protein amount of ATOH7 variants in the presence of a putative dimerization partner (Fig. 4D).

Reduced heterodimerization of patient-derived ATOH7 with E47

Protein-protein interaction enzyme-linked immunosorbent assay (ELISA) was performed in order to investigate the potential impact of ATOH7 patient variants on bHLH protein dimerization. No significant enrichment of either V5-tagged wild type or variant ATOH7 could be detected when exposed to antibody immobilized c-Myc-tagged ATOH7 protein (Fig. 5A and B). A significant enrichment of V5-tagged wild type ATOH7 was detected in the presence of antibody immobilized c-Myc-tagged E47 (Fig. 5C), representing ATOH7-E47 heterodimer formation *in vitro*. The loss-of-function variant p.(Asn46His) as well as the combination of the p.(Ala59) patient variants did not show significant heterodimerization compared to background control. All ATOH7 variants exhibited significantly reduced heterodimerization compared to wild type ATOH7.

Patient-derived ATOH7 variants show reduced DNA-binding

To address the impact on DNA-binding ability of the ATOH7 variants, a DNA-protein interaction ELISA was established.




Figure 2. Compound heterozygous missense variants affecting the p.(Ala59) position of ATOH7. (A) Pedigree of the family with two affected children showing segregation of compound heterozygous variants with ONH. (B) Sanger DNA sequencing electropherograms depicting the compound heterozygous mutations in the two affected siblings. The DNA from the unaffected family members is heterozygous for one mutation (M1). (C) Sequence alignment depicting the two biallelic ATOH7 mutations in the index patient. Vertical bars represent sequencing depth (read coverage range shown in the image is 388–440×). Each horizontal bar represents an aligned sequence; only mismatched nucleotides are shown in color. The Binary Alignment Map (BAM) file format alignment is visualized by IGV.

Double-stranded DNA containing seven consecutive canonical E-box sequences (CAGGTG) was immobilized to immunoassay plates by biotin-streptavidin interaction. HEK293T lysate containing transgenic V5-tagged ATOH7 was incubated with or without lysate containing E47. In concordance with dimerization assays, no DNA-binding of V5-tagged wild type or variant ATOH7 protein could be detected in the presence of immobilized E-box (Fig. 6A). A significant E-box-dependent DNA-binding was observed with wild type ATOH7 in the presence of E47, suggesting DNA-binding of ATOH7-E47 heterodimers (Fig. 6B). Except for the synthetic variant p.(Ala59Gly), all ATOH7 protein variants exhibited significantly reduced DNA-binding compared to wild type ATOH7. DNA-binding of the combination of p.(Ala59) variants, as well as the previously published p.(Asn46His), did not show significant

enrichment compared to negative control [scrambled (scr) E-box], suggesting potential loss of DNA-binding ability. Additionally, the p.(Asn46His) showed significantly lower enrichment compared to all other tested variants.

ATOH7 patient-derived protein variants represent loss-of-function mutations

Since the biological function of ATOH7 is transcriptional activation or regulation of target genes, we performed reporter gene assays. Dual luciferase assays were carried out in HEK293T in order to investigate whether or not the ATOH7 patient-derived variants are capable of transcriptional activation. HEK293T were transfected with plasmid constructs carrying the firefly




Figure 3. Semi-quantitative western blot of V5-tagged ATOH7 normalized to β -tubulin and presented as fold change relative ATOH7 WT. Patient variants display reduced protein amounts in the presence of the putative dimerization partner E47 due to proteasome-mediated degradation. Each bar represents mean \pm SD of three separate experiments. (A) Relative amount of V5-tagged ATOH7. (B) Relative amount of V5-tagged ATOH7 in the presence of co-expressed E47. (C) Relative amount of V5-tagged ATOH7 in the presence of proteasome inhibitor MG-132. (D) Relative amount of V5-tagged ATOH7 in the presence of co-expressed E47 and proteasome inhibitor MG-132. *, **, *** and **** represent P-values of <0.05 , $<10^{-2}$, $<10^{-3}$ and $<10^{-4}$, respectively.

luciferase reporter gene regulated by a minimal promoter containing seven canonical E-box sequences.

Assessment of cells co-expressing wild type ATOH7 displayed a significant increase of luciferase expression over background, which was further enhanced by co-expressing E47 (Fig. 7A), indicating functional ATOH7-E47 dimers. In contrast, patient-derived ATOH7 protein variants did not show a statistically significant transcriptional activation of reporter gene expression, regardless of co-expression with E47. Similarly, the loss-of-function variant p.(Asn46His) did not show any transcriptional activation, which is consistent with previously published data (25). Interestingly, a significant decrease of base level luciferase activity could be seen when expressing p.(Asn46His) in the presence of E47. The artificial variant p.(Ala59Gly) displayed statistically significant transcriptional activation; however, this was reduced in magnitude relative to wild type ATOH7 (Fig. 7B). Co-expression of wild type ATOH7 and patient variants, mimicking the carrier status of the parents, displayed a minor reduction in luciferase reporter

expression compared to wild type ATOH7. In order to account for potentially reduced ATOH7 variant protein expression when co-expressing E47, luciferase assays were also carried out on MG-132-treated samples (Supplementary Material, Fig. S6). The loss of transcriptional activation of the ATOH7 patient variants remained. Confocal microscopy of fluorescently stained V5-tagged ATOH7 was additionally performed in order to verify that the measured loss of transcriptional activation is not due to protein mislocalization. The patient ATOH7 variants retained their nuclear localization (Supplementary Material, Fig. S7).

Discussion

Patient-derived ATOH7 variants affect protein heterodimerization

ATOH7 is a class II bHLH transcription factor, characterized by tissue-specific expression, low capability of homodimerization and favored heterodimerization with class I bHLH transcription




Figure 4. ATOH7 protein turnover quantified through semi-quantitative western blot of V5-tagged ATOH7 normalized to β -tubulin and presented as fold change relative to ATOH7 WT before CHX treatment (time point zero). Each point represents mean \pm SEM of three separate experiments. Fitted lines represent linear regression of protein turnover, showing a negative relation between relative protein amount and time (dF1,11 and $P < 0.001$ for all regressions). (A) Turnover of ATOH7. (B) Turnover of ATOH7 in the presence of co-expressed E47. (C) Turnover of ATOH7 in the presence of proteasome inhibitor MG-132. (D) Turnover of ATOH7 in the presence of co-expressed E47 and proteasome inhibitor MG-132. Statistical differences were tested by multiple comparisons of regression slopes. Asterisk symbols (*) represent significance vs. ATOH7 WT and cross symbols (+) represent difference relative to the previously published loss-of-function variant p.(Asn46His). *, **, *** and **** represent P-values of <0.05 , $<10^{-2}$, $<10^{-3}$ and $<10^{-4}$, respectively.

factors, also known as E proteins (52). The latter characteristics support our observation that wild type ATOH7 protein could not be enriched in ELISA assays through protein homodimerization (Fig. 5) nor through E-box DNA-binding (Fig. 6) in the absence of the putative heterodimerization partner E47. This finding is supported by the results of previous work by Prasov *et al.* (25), who observed ATOH7-E47 protein heterodimers but not ATOH7 homodimers by means of electrophoretic mobility shift assay. Interestingly, we were able to measure E-box-mediated transcriptional activation induced by wild type ATOH7 in the absence of E47 co-expression (Fig. 7). It is likely that endogenously expressed E47 and/or other class I bHLH binding partners may have contributed to transcriptional activation through heterodimerization with transgenic ATOH7. It is also possible that short-lived functional homodimers are stable inside the nucleus of a living cell but not in cell-free conditions.

Our findings suggest that the two characterized ATOH7 missense variants at protein position 59 lead to significantly reduced heterodimerization. The 59th amino acid position of ATOH7 is a highly conserved residue within the HLH domain, important for bHLH transcription factor dimerization. A closely related homolog of ATOH7 is the class II bHLH transcription factor neuronal differentiation 1 (NEUROD1). The crystal structure of the E47-NEUROD1 heterodimer has been previously identified through X-ray crystallography (53). The alanine at the 59th position of ATOH7 coincides with alanine at position six of the first helix in the NEUROD1 amino acid sequence (Supplementary Material, Fig. S8), which has been identified to be part of the E47-NEUROD1 dimer interface and thus supports our finding that mutations in this position have a deleterious impact on heterodimerization.

Interestingly, the previously described loss-of-function variant p.(Asn46His) did not show significant heterodimerization, despite being located within the DNA-binding basic domain of ATOH7 and thus outside of the HLH domain. It is possible that the substitution of asparagine for histidine, which introduces an imidazole ring and thus a net positive charge of the amino acid residue, may influence the secondary protein structure and thus the overall ability of the variant ATOH7 monomer to form dimers with E47.

ATOH7 heterodimerization affects DNA-binding and transcriptional activation

Interestingly, both of the patient-derived ATOH7 variants also resulted in decreased/lost ability of the ATOH7 protein to bind E-box DNA (Fig. 6), despite the fact that these amino acid substitutions are located outside the DNA-binding basic domain. This may be explained as a direct consequence of impaired and decreased heterodimerization, which disrupts DNA-binding of bHLH proteins (54). These functional aberrations ultimately lead to loss of transcriptional activation of the two ATOH7 patient-derived variant proteins, as observed in luciferase reporter assays (Fig. 7).

The artificial ATOH7 p.(Ala59Gly) variant was used as a control throughout the functional characterization. Due to the similar properties of alanine and glycine, we expected little or no impact on protein function. The variant displayed reduced dimerization and DNA-binding; however, transcriptional function/activation was retained and this variant may therefore be considered a hypomorphic allele.




Figure 5. ATOH7 homodimerization and heterodimerization quantified through protein-protein interaction ELISA. V5-tagged ATOH7 from cell lysate was bound by immobilized c-Myc-tagged dimerization partner. Results are normalized to background values (sample, no dimerization partner) and presented as fold change relative to untagged control (V5-tagged ATOH7 WT, untagged dimerization partner). Bars indicate mean of three independent experiments with three technical replicates \pm SD. (A) Dimerization with immobilized c-Myc-tagged ATOH7 WT. (B) Dimerization with immobilized c-Myc-tagged ATOH7 variants. (C) Dimerization with immobilized c-Myc-tagged E47. Asterisk symbols (*) represent significance vs. untagged control. *, **, *** and **** represent P-values of <0.05 , $<10^{-2}$, $<10^{-3}$ and $<10^{-4}$, respectively.

In contrast, the published p.(Asn46His) variant, located in the DNA-binding basic domain, failed to bind DNA and activate transcription. This is in concordance with previously reported functional characterization (25) as well as the crystal structure of E47-NEUROD1 identifying the amino acid position to be an important residue contributing to DNA-binding (53). Interestingly, a significant decrease of transcriptional activation relative to background level was seen in the presence of expressed E47. This could signify a dominant negative effect on protein function with an unknown molecular basis and may potentially explain




Figure 6. DNA-binding of ATOH7 quantified through DNA-protein interaction ELISA. V5-tagged ATOH7 from cell lysate was mixed with lysate containing c-Myc-tagged dimerization protein and bound by biotin-streptavidin immobilized E-box DNA. Results are normalized to background values (sample, no E-box DNA) and presented as fold change relative to scr control (ATOH7 WT, scr E-box). Each bar represents mean \pm SD of three triplicates of three separate experiments. (A) V5-ATOH7 DNA-binding in the presence of c-Myc-tagged ATOH7. (B) V5-ATOH7 DNA-binding in the presence of c-Myc-tagged E47. Asterisk symbols (*) represent significance vs. scr control. *, **, *** and **** represent P-values of <0.05 , $<10^{-2}$, $<10^{-3}$ and $<10^{-4}$, respectively. The pilcrow sign (†) indicates significant reduction of variant p.(Asn46His) compared to all other ATOH7 variants ($P < 0.0001$).

why this variant causes a different ocular phenotype compared to the investigated patient-derived variants.

Heterodimerization stimulates proteasome-dependent degradation

Co-expression of ATOH7 protein variants and E47 showed a significant reduction in protein amounts, which was abolished by the proteasome inhibitor MG-132 (Fig. 3). Interestingly, patient variant proteins, and to a lesser extent the previously characterized loss-of-function variant p.(Asn46His) and the synthetic variant p.(Ala59Gly), displayed an accelerated proteasome-dependent turnover in the presence of E47 (Fig. 4), suggesting an additional mechanism by which ATOH7 variants may show reduced function *in vivo*.

Proteasome-mediated degradation of ubiquitinated bHLH factors has been observed in previous studies (55). Dimerization of several human bHLH proteins, including E47, with the *C. elegans* helix-loop-helix 2 (HLH-2) has been described as inducing dimerization-dependent proteasomal degradation (56). However, compromising protein dimerization by mutating important helix 1 residues abolished the dimerization-dependent degradation, in contrast to our findings. It is possible that although abolished dimerization leads to increased bHLH monomer stability,




Figure 7. Transcriptional reporter gene activation by ATOH7 and its variants quantified through dual luciferase assay. HEK293T cells were transfected with plasmid firefly luciferase gene expressed under the control of an E-box containing minimal promoter, Renilla luciferase under the control of a cytomegalovirus (CMV)-promoter and pcDNA3.1 constructs containing ATOH7 or TCF3 under the control of a cytomegalovirus (CMV)-promoter. Firefly luminescence of each sample was normalized to Renilla luciferase luminescence and is presented as relative background control (no ATOH7 expression) in (A) and relative ATOH7 WT in (B). Bars indicate mean of three independent experiments with four biological replicates \pm SD. Light grey bars represent luminescence in the absence of E47; black bars represent luminescence in the presence of E47. Asterisk symbols (*) represent significance vs. control without E47 expression; cross symbols (+) represent significance vs. control with E47 expression. *, **, *** and **** represent P-values of <0.05 , $<10^{-2}$, $<10^{-3}$ and $<10^{-4}$, respectively.

reduced but retained dimerization may lead to the opposite effect due to distorted dimer structure or simply to reduced binding of chromatin. The impact of bHLH dimerization on protein degradation may indeed depend on multiple factors. A published study reported greatly increased stability of bHLH DNA-binding inhibitor proteins (ID proteins) when forming heterodimers with E47 (57). The precise mechanisms of how this selective degradation occurs in the case of the described ATOH7 patient SNVs are yet to be elucidated.

ATOH7 mutations as a genetic basis for an ocular phenotype dominated by ONH

Given the significance of ATOH7 as an early retinal transcription factor specifying RGC fate, it is feasible that non-functional ATOH7 mutations lead to a severe reduction in differentiated RGCs and therefore affect optic nerve development. Furthermore, we consider the observed anomalies of the retinal vasculature, including tortuosity and incomplete peripheral vascularization, to be an indirect consequence of reduced




Figure 8. A schematic overview of proposed interactions in functional changes of the ATOH7 protein as a consequence of non-synonymous p.(Ala59) mutations. Plus (+) and minus (-) signs indicate up- and down-regulation, respectively; cross (X) indicates loss-of-function.

RGC differentiation. This is supported by the observation that the majority of RGCs in the human retina are generated in gestational weeks 7–9 (58), which is followed by the development of the primary retinal vasculature at the RNFL/RGC interface at 14–15 weeks of gestation (28). This differentiates our findings from exudative vitreoretinopathies, where the primary cause for the vascular manifestations is incomplete angiogenesis due to impacted Wnt and Norrin signaling (59).

In this report, we present various characteristics of the addressed ATOH7 patient SNVs that culminate in a complete loss of function, thus supporting the hypothesis that p.(Ala59Thr) and p.(Ala59Val) are mutations likely causative of the described eye phenotype. This statement is based on several observations:

(1) The rare compound heterozygous ATOH7 mutations segregate with ONH in an autosomal recessive pattern, (2) both mutations affect the well-conserved 59th amino acid residue within the functionally important bHLH domain of ATOH7, (3) the mutations are predicted deleterious by three different algorithms, (4) the mutations show significantly increased proteasomal degradation and reduction in protein levels, (5) heterodimerization with E47 is reduced and consequently E-box DNA-binding of the heterodimer is reduced or abolished and (6) complete loss of transcriptional activation is induced through the E-box containing promoter, comparable to the previously established loss-of-function mutation p.(Asn46His). A proposed schematic model of the functional consequences induced by the p.(Ala59) mutations is presented in Figure 8.

As the mutant ATOH7 proteins are likely able to form heterodimers but are functionally inactive, it is also possible that they act as dominant-negative proteins in analogy to the Id class of bHLH factors (60). The effects of the described ATOH7 mutations could thus have a more global effect on the developing retina beyond what is possible to address in the present study. Although this report characterizes several key mechanisms by which loss of transcriptional function may occur in the described

patient variants, it would be desirable to perform functional characterization in an appropriate developmental environment as opposed to observations based on transgene expression in a cell line. An animal model or hiPSC-derived retinal organoid would provide the benefit of addressing transcriptome and DNA target alterations, as well as the morphology of RGCs.

Molecular basis of FVH

FVH is a reduction in or absence of the foveal pit and foveal avascular zone (61). FVH may be diagnosed and graded based on OCT findings (30). Grade 1 FVH is characterized by a shallow foveal pit and the presence of visible extrusion of the inner retinal layers. In grade 2 FVH, the foveal pit is completely absent. Grade 3 FVH is similar to grade 2, but without visible outer segment lengthening, whilst in grade 4 FVH it is not possible to visibly differentiate the presumed fovea from the parafovea (30). OCT examination of the father revealed a shallow foveal pit and continuity in the outer nuclear layer and outer segment, consistent with grade 1 FVH. Signs of FVH were also found in the visually affected siblings suffering from ONH, where the index patient displayed findings consistent with grade 1 FVH and the sister showed a total absence of foveal pit consistent with grade 2 FVH.

Several conditions have been associated with FVH, including ocular albinism, aniridia and achromatopsia (62). FVH may also present as an isolated trait, commonly in association with nystagmus and low vision, although asymptomatic cases as well as cases with minor vision deficits have been reported (63–65). Autosomal dominant FVH (OMIM #136520) is caused by mutations in *PAX6* (40). Although autosomal dominant FVH may occur in isolation, it is commonly associated with nystagmus and present in patients with aniridia or albinism (66) and sporadically in patients with presenile cataracts (67). Autosomal recessive FVH (OMIM #609218) is caused by solute carrier family 38 member 8 (*SLC38A8*) mutations (51). A common feature in these patients is optic nerve decussation defects and anterior segment dysgenesis in the absence of albinism (68).

In a study examining OCT changes in association with ONH, over 80% of the investigated cases of ONH also presented findings consistent with FVH (69). It is therefore most likely that FVH and the vascular abnormalities observed in the affected siblings share a common developmental background with ONH in the affected siblings. Conversely, FVH in the absence of ONH in the father may be due to a simple heterozygous *ATOH7* mutation; however, we consider this unlikely as the remaining three unaffected family members are carrying heterozygous *ATOH7* variants affecting the same amino acid residue and the unaffected brother is carrying the particular *ATOH7* variant. FVH in the father may therefore be a result of an unknown independent gene mutation.

NGS data analysis revealed *OPA3* as a possible candidate for FVH. *OPA3* encodes an outer mitochondrial membrane protein implicated in mitochondrial fission, apoptosis and regulation of lipid metabolism; however, the exact function remains to be fully elucidated (70–72). High expression of *OPA3* in the brain, retina, optic nerve, and lens has been observed throughout mouse embryogenesis (73). Mutations in *OPA3* have been previously linked to autosomal recessive 3-methylglutaconic aciduria with optic atrophy and extrapyramidal symptoms, also known as Costeff syndrome (74), as well as autosomal dominant optic atrophy and cataract (75).

The observed *OPA3* SNV is shared between the father and the two affected siblings; however, it is also present in the older

unaffected sister. Although segregation of the *OPA3* SNV with FVH is inconsistent in this family, it may be possible that *OPA3* mutations cause FVH with incomplete penetrance, analogous to the incomplete penetrance described in autosomal dominant optic atrophy (76). An alternative possibility is that FVH occurs as a result of combined *OPA3* p.(Gly15Arg) and *ATOH7* p.(Ala59Val) variants. This specific combination of variants is present exclusively in the family members presenting FVH and would explain the absence of the FVH phenotype in the other family members.

Summary

The presented cases are the first report of compound heterozygous *ATOH7* mutations associated with a phenotype predominated by ONH. Additional findings include FVH, as well as vascular abnormalities, which may be a consequence of ONH or pleiotropic observations. Analysis of this gene should be performed in patients with bilateral ONH, despite previous controversial reports.

Materials and Methods

OCT and fundus imaging

Macular and circumpapillary OCT was performed under non-mydriatic conditions using a single Heidelberg Spectralis® device (Heidelberg Engineering GmbH, Heidelberg Germany; software version 6.9a) by one of two authors (J.V.M.H., C.G.-K.), both of whom were experienced in acquiring and analyzing OCT data. The following macula scan parameters were employed: high resolution (HR) mode; 31 horizontally aligned sections separated by 45 µm covering a retinal area of 30° horizontally × 25° vertically; 15 Automatic Real-Time Tracking (ART) scans averaged per section; centration on the fovea or presumed fovea. Circumpapillary scans were acquired with the following scan parameters: HR mode; 12° scan diameter; 100 ART scans averaged; centration on the visible center of the optic nerve head. It was necessary to amend the precise OCT acquisition settings used (with the goal of reducing the time necessary to acquire OCT data) when scanning the index patient and her affected sister, as their reduced visual function (potentially exacerbated by their young age) resulted in poor or unstable fixation. Despite this pragmatic approach, it was not possible to acquire all OCT scans in both affected patients: in the index patient, only a macula scan could be obtained and then only in the LE; in the affected sister, a macula scan was successfully performed in the RE only, and circumpapillary scans in both eyes; however, the scan from the LE was of insufficient quality (77) and was excluded from further analysis.

All OCT scans were inspected by a single author (J.V.M.H.), and the software-generated definitions of the inner limiting membrane and Bruch's membrane were verified and (when necessary) corrected for all sections of the OCT scan. Following this verification, the 1, 3, 6 mm Early Treatment of Diabetic Retinopathy Study (ETDRS) grid was centered upon the fovea or presumed fovea, and a measure of total macular volume (TMV; in mm³) obtained from the proprietary software supplied by Heidelberg Engineering. For the circumpapillary scans, the software-generated definition of the RNFL was also verified and, when necessary, corrected; global RNFL thickness (averaged from superior, inferior, temporal and nasal quadrants) was obtained from the proprietary software. Macula scans were automatically segmented, with author J.V.M.H. verifying and, when necessary, correcting the software-generated definitions

of RNFL, the ganglion cell layer (GCL) and the inner plexiform layer (IPL). The macular scan of the index patient was judged to be of insufficient quality to reliably distinguish the retinal layers and was thus not segmented. Due to the difficulty in accurately distinguishing the border of GCL and IPL, these layers were aggregated and subsequently treated as one layer, the GCIPL (78). Following verification of these intra-retinal boundaries, the 1, 2.22, 3.45 mm ETDRS grid was centered upon the fovea or presumed fovea, and GCIPL volume was quantified as the sum of the volumes (in mm³) of GCL and IPL as obtained from the software provided by Heidelberg Engineering. Structural measures of the retinal layers distal to IPL were neither verified nor analyzed for the purposes of this study.

Wide-angle fundus imaging was performed on the affected sister only with the Optomap[®] (Optos, Dunfermline, United Kingdom).

Magnetic resonance imaging

MRI was performed on a 3-Tesla MR scanner (GE Signa MR750) with an 8-channel head coil. The MRI protocol comprised thin-slice (2.5 mm) T2-weighted fat-saturated fast spin-echo images of the orbits in coronal orientation.

Whole exome sequencing

WES was performed with venous blood DNA. Libraries were prepared according to Nextera Rapid Capture Exome protocol (Illumina, San Diego, CA, USA) to generate 75 bp paired-end reads. Sequence read alignment, indexing of the reference genome and variant calling were performed using a pipeline based on Burrows-Wheeler aligner at the BaseSpace Onsite (Illumina, San Diego, CA, USA). Annotation of the variants was performed using Alamut-batch (Interactive Biosoftware, Rouen, France), and variants were visualized on Alamut Viewer 2.3 (Interactive Biosoftware, Rouen, France) and Integrative Genomics Viewer (IGV) 2.6 (79) (Broad Institute and the Regents of the University of California, CA, USA).

In order to identify the most likely disease-causing variants, a variant filtering pipeline was utilized according to our previous publication (80). Filtering of variants was performed primarily on a set of genes associated with ONH and/or FVH according to Supplementary Material, Table S1, and was also extended to a gene panel for eye diseases (<https://www.medmolgen.uzh.ch/de/services/Hauptgene.html>, accessed 01.07.2019) when applicable. Owing to the rare occurrence of ONH and FVH in the population, only variants with frequency below 1% were chosen on dbSNP MAF, 1000 Genomes, Exome Sequencing Projects and Exome Aggregation Consortium.

Polymerase chain reaction and Sanger sequencing

PCR targeting ATOH7 exon 1 was performed by 2-fragment PCR. Fragment one was amplified in 25 µL total volume using 1× Amplitaq Gold[™] 360 Master Mix (Applied Biosystems, Foster City, CA, USA), 1× 360 GC Enhancer, 0.4 µM primers (ATOH7_Ex1_for4 and ATOH7_Ex1_rev2; Supplementary Material, Table S2). Cycling conditions were as follows: 95°C for 15 min; 35 cycles of (95°C for 1 min, 60°C for 1 min, 72°C for 2 min); 72°C for 10 min. Fragment two was amplified in 25 µL total volume using 1.25 U HOT FIREPol[®] DNA Polymerase (Solis Biodyne, Tartu, Estonia), 1× reaction buffer B1, 1.5 mM

MgCl₂, 0.2 mM dNTPs and 0.3 µM primers (ATOH7_Ex1_for2 and ATOH7_Ex1_rev; Supplementary Material, Table S2). Cycling conditions were as follows: 98°C for 2 min; 20 cycles of (98°C for 10 s, 72°C for 2 min); 72°C for 10 min. PCR targeting OPA3 exon 1 was performed in 50 µL total volume using 5 U Phusion[®] High-Fidelity DNA Polymerase (New England Biolabs; Ipswich, MA, USA), 1× GC buffer, 1× S-solution (Solis Biodyne, Tartu, Estonia), 0.2 mM dNTPs and 0.5 µM primers (OPA3_F and OPA3_R; Supplementary Material, Table S2). Cycling conditions were as follows: 98°C for 2 min; 20 cycles of (98°C for 10 s, 72°C for 2 min); 72°C for 10 min.

Sanger sequencing was performed by BigDye Terminator 3.1 (Applied Biosystems, Foster City, CA, USA) according to the manufacturer's instructions using 3130xl Genetic Analyzer (Applied Biosystems, Foster City, CA, USA).

Cloning of expression vectors

Full-length coding sequence of wild type ATOH7 (NM_145178.3) was amplified from gDNA of a control patient by PCR in 50 µL total volume with 3 U Pfu[®] Polymerase (Promega, Madison, WI, USA), 1× Pfu buffer, 0.16 mM dNTPs and 0.2 µM primers (ATOH7_CACC_FWD and ATOH7_STOP_REV; Supplementary Material, Table S2). Cycling conditions were as follows: 95°C for 2 min; 35 cycles of (95°C for 45 s, 58°C for 30 s, 72°C for 3.5 min); 72°C for 10 min. Human TCF3-E47 cDNA (NM_001136139) was de novo synthesized (OriGene, Rockville, MD, USA; cat. RC227647). Expression constructs were created by subcloning into pcDNA[™]3.1/nV5-DEST mammalian expression vector (Invitrogen, Carlsbad, CA, USA) expressing either N-terminal V5 tag or C-terminal c-Myc tag.

ATOH7 variants were constructed by site-directed mutagenesis of pcDNA3.1-ATOH7 construct. PCR reactions were performed by Phusion[®] High-Fidelity DNA Polymerase as described earlier using mutagenesis primers (Supplementary Material, Table S3). PCR products were purified by NucleoSpin[®] Gel and PCR Clean-up (Macharey Nagel, Oensingen, Switzerland), digested by DPNI (New England Biolabs, Ipswich, MA, USA) for 2 h and transformed in TOP10 competent cells (Thermo Fisher Scientific, Waltham, MA, USA). ATOH7 variants were verified by Sanger sequencing after which ATOH7 CDS was re-cloned into pcDNA3.1 vector to avoid possible vector mutations introduced by PCR.

Cell culture

HEK293T were cultured at 36.5°C and 5% CO₂ in Dulbecco's Modified Eagle Medium (Gibco, Waltham, MA, USA; cat. 41966-029), supplemented with 10% Fetal Calf Serum (Eurobio, Courtaboeuf, France) and 1% penicillin/streptomycin (Corning, Corning, NY, USA). Cells were split at 80–90% confluence. 24 h prior to transfection, cells were seeded at a density of 5 × 10⁴ cells/cm². Transfections were performed using branched polyethylenimine (PEI; Mw ~ 25 000; Sigma-Aldrich, St. Louis, MO, USA) in ratio PEI:DNA 3:1 unless otherwise stated. Cells were harvested 24 h post-transfection.

Immunocytochemistry

HEK293T were cultured on Poly-L-Lysine pre-coated 22 × 22 mm coverslips inserted into six-well plates. Each well was

co-transfected with 1.5 μ g of pcDNA3.1-V5-ATO7 and 1.5 μ g of either empty vector or pcDNA3.1-TCF3-c-Myc. A series of three washes with phosphate buffered saline (PBS) were performed between each step. Cells were fixed in 4% paraformaldehyde diluted in PBS for 15 min, followed by permeabilization in 0.01% Triton X-100 diluted in PBS for 20 min. Blocking was performed in 5% bovine serum albumin (BSA) solved in PBS for 30 min. Primary antibody incubation was performed at room temperature for 1 h using rabbit anti-V5 ab (1:200; [Supplementary Material, Table S4](#)) and mouse anti c-Myc ab (1:200; [Supplementary Material, Table S4](#)) diluted in blocking solution. Secondary antibody incubation was performed at room temperature for 1 h using Alexa Fluor[®] 488 goat anti-rabbit ab (1:1000; [Supplementary Material, Table S4](#)) and Alexa Fluor[®] 647 goat anti-mouse ab, (1:1000; [Supplementary Material, Table S4](#)) diluted in blocking solution. Coverslips were mounted onto slides using Fluoromount-G[®] (Southern Biotech, Birmingham, AL, USA) containing 4',6-diamidino-2-phenylindole. Samples were imaged using a Leica SP8 confocal microscope (Leica Microsystems, Wetzlar, Germany) at $\times 60$ magnification.

Western blot

HEK293T were cultured in six-well plates. Each well was co-transfected with 1.5 μ g of pcDNA3.1-V5-ATO7 and 1.5 μ g of either pcDNA3.1 vector or pcDNA3.1-TCF3-c-Myc. Cells were washed twice with PBS, scraped down and centrifuged at 1000g. Cell pellets were re-suspended in lysis buffer consisting of 50 mM Tris-HCl (pH 7.5), 150 mM NaCl 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulphate, 1% Triton X-100, 1 tabl./50 ml cComplete[™] protease inhibitor cocktail (Roche; Basel, Switzerland) and incubated for 30 min. Whole cell lysate was centrifuged at 14 000g for 10 min and supernatant was collected. Total protein concentration was measured using Pierce[™] bicinchoninic acid assay (BCA) Protein Assay Kit (Thermo Scientific, Waltham, MA, USA) and adjusted to 1500 μ g/ml. Samples were denatured by boiling in loading buffer (250 mM Tris, pH 6.8, 10% sodium dodecyl sulphate, 50% glycerol, 5% β -mercaptoethanol, 0.5% bromophenol blue) at 99°C for 5 min. SDS-PAGE was performed in 12.5% acrylamide gels. Electrophoresis was performed in SDS run buffer (125 mM Tris, 0.96 M glycine, 17.3 mM sodium dodecyl sulphate) at 200 V for 40 min. Gels were blotted onto PVDF western blotting membranes (Roche, Basel, Switzerland) in semi-dry condition using blotting buffer (48 mM Tris, 3.92 mM glycine, 1.30 mM sodium dodecyl sulfate, 20% methanol) at 15 V for 40 min. Blots were blocked in Tris-buffered saline containing 5% milk (TBS-T) overnight at 4°C. Immunoblotting was performed by incubation in TBS-T with mouse anti-V5 (1:5000; [Supplementary Material, Table S4](#)) or mouse anti-c-Myc ab (1:400; [Supplementary Material, Table S4](#)) for 1 h and subsequent incubation with sheep anti-mouse HRP-conjugated ab (1:2000; [Supplementary Material, Table S4](#)) for 1 h. Reprobing was performed by two 10 min incubations in stripping buffer (0.20 M glycine, 3.47 mM SDS, 1% ml Tween-20, pH 2.2) followed by blocking and immunostaining using rabbit anti- β tubulin ab (1:1000; [Supplementary Material, Table S4](#)) and donkey anti-rabbit conjugated ab (1:2000; [Supplementary Material, Table S4](#)). Western lightning plus-ECL (PerkinElmer, Waltham, MA, USA) was applied for 1 min to the blots and imaging was performed in Chemidoc XRS+ (Bio-Rad Laboratories, Hercules, CA, USA). Quantification was performed using Image Lab 5.0 software (Bio-Rad Laboratories, Hercules, CA, USA). Relative protein expression was quantified by normalizing to β -tubulin and expressed as

fold change relative to wild type ATO7. Means were calculated from the results of three independent measurements ($n=3$) \pm SD.

Cycloheximide chase assay

Cells were treated with proteasome inhibitor MG-132 (Calbiochem, San Diego, CA, USA) 20 h post transfection at a final concentration of 20 mM. Cells not treated with MG-132 were supplemented with equal volume DMSO (Sigma-Aldrich, St. Louis, MO, USA). CHX (Sigma-Aldrich, St. Louis, MO, USA) was added 24 h post transfection at a final concentration of 100 μ g/ml. Cells were collected at 0, 1, 2 and 4 h after CHX addition, and western blot was performed according to the above-described protocol. Relative protein expression was quantified by normalizing to β -tubulin and expressed as fold change relative to ATO7 at time point zero. Means were calculated from the results of three independent experiments ($n=3$) \pm SEM. Linear regression was fitted for the time course of each variant (dF1,11, $P < 0.001$). Assessment of statistical differences was performed by multiple comparisons of the regression slopes using one-way analysis of variance (ANOVA) corrected for multiple comparisons using Tukey's test and 95% confidence intervals.

Protein-protein interaction enzyme-linked immunosorbent assay

Each incubation was preceded by rinsing wells three times with a wash buffer consisting of PBS containing 0.1% Tween-20. Nunc MaxiSorp[™] flat-bottom 96-well plates (Invitrogen; Carlsbad, CA, USA) were coated overnight at 4°C with 2.5 μ g/ml mouse anti c-Myc monoclonal antibody 9E10 ([Supplementary Material, Table S4](#)) diluted in coating buffer (50 mM carbonate/bicarbonate, pH 9.6). On the following day, unspecific binding sites were blocked by 2 h incubation at 37°C with PBS containing 3% bovine serum albumin (BSA).

HEK293T were transfected with 20 μ g of either pcDNA-V5-ATO7, pcDNA3.1-ATO7-c-Myc or pcDNA3.1-TCF3-c-Myc construct. Samples were lysed in IP lysis buffer (25 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% NP-40, 1 mM EDTA, 5% glycerol, protease inhibitor cocktail) and centrifuged at 14 000g for 10 min. The supernatant was collected and total protein concentration was normalized to 1000 μ g/ml using Pierce[™] BCA Protein Assay Kit (Thermo Scientific, Waltham, MA, USA). Lysates containing c-Myc-tagged, respectively, V5-tagged recombinant protein were mixed 1:1 before incubation in prepared ELISA plates overnight at 4°C. Primary antibody incubation was performed with rabbit anti-V5 polyclonal antibody (1:1000; [Supplementary Material, Table S4](#)) diluted in wash buffer for 90 min at 37°C. Secondary antibody incubation was performed with goat anti-rabbit HRP-conjugated antibody (1:1000; [Supplementary Material, Table S4](#)) diluted in wash buffer for 1 h at 37°C. Colorimetric detection was performed using 3,3',5,5'-tetramethylbenzidine (Sigma-Aldrich, St. Louis, MO, USA) and measured at 690 nm using ELx808[™] Absorbance Microplate Reader (Bio-Tek, Bad Friedrichshall, Germany). Raw data consisted of kinetic velocity maxima calculated on 100 repeated absorbance scans interspaced by 5 s intervals of shaking. Each sample measurement was normalized to background measurements consisting of sample detection in plates without immobilized c-Myc-tagged dimerization protein. Results were presented as fold change relative to

the no dimerization control consisting of V5-tagged wild type ATOH7 and no immobilized c-Myc-tagged dimerization partner. Means were calculated from the results of three independent experiments, each with three technical replicate measurements ($n=3$) \pm SD.

DNA–protein interaction enzyme-linked immunosorbent assay

The following procedure is based on the protocol for protein–protein interaction ELISA. Coating with capture antibodies was substituted by 10 $\mu\text{g/ml}$ streptavidin diluted in coating buffer. Biotinylated E-box DNA consisting of seven tandem E-box binding sites (CAGGTG) and scr E-box dimers were prepared by incubating 0.5 μM of sense and 5-biotinylated antisense single-stranded oligodeoxynucleotides (Supplementary Material, Table S5) in STE buffer (100 mM NaCl; 10 mM Tris-HCl, pH 8.0; 1 mM EDTA) for 5 min at 95°C and cooling at room temperature for 30 min. Wells were incubated with either E-box dimer or scr dimer solution for 1 h at 37°C. Blocking and lysate preparation was performed as above. Samples were incubated by mixing lysate from ATOH7 expressing cells with either lysate from negative controls or lysate from E47 expressing cells. ssDNA from salmon testes (1:50; Sigma-Aldrich, St. Louis, MO, USA) was added to samples to reduced unspecific protein-DNA-binding. Primary antibody incubation consisting of mouse anti-V5 monoclonal antibody (Supplementary Material, Table S4) for 90 min in 37°C. Secondary antibody incubation consisted of sheep anti-mouse HRP-conjugated antibody (Supplementary Material, Table S4) for 1 h in 37°C. Each sample measurement was normalized to background measurements consisting of sample detection in plates without immobilized E-box DNA. Results were presented as fold change relative to scr control consisting of V5-tagged wild type ATOH7 measured in plates containing immobilized scr E-box. Means represent three independent experiments each with three technical replicate measurements ($n=3$) \pm SD.

Dual luciferase assay

HEK293T were co-transfected with 43.75 ng of firefly luciferase vector pGL4.23 (Promega, Madison, WI, USA) containing seven tandem E-box binding sites (CAGGTG) inserted in front of a minimal promoter, 43.75 ng of Renilla luciferase control plasmid pGL4.75 (Promega, Madison, WI, USA), 87.50 ng of pcDNA3.1-V5-ATOH7 construct and 0.22 ng of either pcDNA3.1 vector or pcDNA3.1-TCF3-c-Myc in ratio PEI:DNA 4.5:1. Transcriptional activation was determined using Dual-Glo[®] Luciferase Assay System (Promega, Madison, WI, USA) according to the manufacturer's manual. Measurements were performed in Luminoskan Ascent (Thermo Labsystems, Helsinki, Finland). Individual firefly luminescence measurements were divided by corresponding Renilla luminescence measurements. Results were presented as fold change relative to background control consisting of transfections of pGL4.23/4.75 and empty pcDNA3.1 vector or pcDNA3.1-TCF3-c-Myc. Means represent three independent experiments each with four biological replicate measurements ($n=12$) \pm SD.

Statistical analysis

Calculations and figures were made in GraphPad PRISM v6.07 (GraphPad Software Inc., San Diego, CA, USA). Unless stated elsewhere, testing of significance was performed by two-way

ANOVA comparing simple effects within columns, corrected for multiple comparisons using Šidák correction, and 95% confidence intervals.

Supplementary Material

Supplementary Material is available at HMG online.

Acknowledgements

We would like to thank Peter Breitschmid and Anouk Scherrer at the Department of Ophthalmology, University Hospital of Zurich, for fundus photography of the patients. We thank Jordi Maggi at the Institute of Medical Molecular Genetics, University of Zurich, for technical support. We are grateful to the patients and their family for their voluntary participation. We acknowledge the Center for Microscopy and Image Analysis at the University of Zurich for their assistance and usage of equipment.

Funding

University of Zurich; Albert Bruppacher Stiftung (to J.V.M.H.); Stiftung OPOS zugunsten von Wahrnehmungsbehinderten (to J.V.M.H.).

Conflict of Interest Statement

None declared.

References

- Patel, L., McNally, R.J.Q., Harrison, E., Lloyd, I.C. and Clayton, P.E. (2006) Geographical distribution of optic nerve hypoplasia and Septo-optic dysplasia in Northwest England. *J. Pediatr.*, **148**, 85–88.
- Teär Fahnehjelm, K., Dahl, S., Martin, L. and Ek, U. (2014) Optic nerve hypoplasia in children and adolescents; prevalence, ocular characteristics and behavioural problems. *Acta Ophthalmol.*, **92**, 563–570.
- Mohney, B.G., Young, R.C. and Diehl, N. (2013) Incidence and associated endocrine and neurologic abnormalities of optic nerve hypoplasia. *JAMA Ophthalmol.*, **131**, 898.
- Brodsky, M.C. (1994) Congenital optic disk anomalies. *Surv. Ophthalmol.*, **39**, 89–112.
- Siatkowski, R.M., Sanchez, J.C., Andrade, R. and Alvarez, A. (1997) The clinical, neuroradiographic, and endocrinologic profile of patients with bilateral optic nerve hypoplasia. *Ophthalmology*, **104**, 493–496.
- Azuma, N., Yamaguchi, Y., Handa, H., Tadokoro, K., Asaka, A., Kawase, E. and Yamada, M. (2003) Mutations of the PAX6 gene detected in patients with a variety of optic-nerve malformations. *Am. J. Hum. Genet.*, **72**, 1565–1570.
- Garcia-Filion, P., Epport, K., Nelson, M., Azen, C., Geffner, M.E., Fink, C. and Borchert, M. (2008) Neuroradiographic, Endocrinologic, and ophthalmic correlates of adverse developmental outcomes in children with optic nerve hypoplasia: a prospective study. *Pediatrics*, **121**, e653–e659.
- Kelberman, D. (2006) Mutations within Sox2/SOX2 are associated with abnormalities in the hypothalamo-pituitary-gonadal axis in mice and humans. *J. Clin. Invest.*, **116**, 2442–2455.
- Chen, C.A., Yin, J., Lewis, R.A. and Schaaf, C.P. (2017) Genetic causes of optic nerve hypoplasia. *J. Med. Genet.*, **54**, 441–449.

10. Dattani, M.T., Martinez-Barbera, J.-P., Thomas, P.Q., Brickman, J.M., Gupta, R., Mårtensson, I.-L., Toresson, H., Fox, M., Wales, J.K.H., Hindmarsh, P.C. et al. (1998) Mutations in the homeobox gene *HESX1/Hesx1* associated with septo-optic dysplasia in human and mouse. *Nat. Genet.*, **19**, 125–133.
11. McNay, D.E.G., Turton, J.P., Kelberman, D., Woods, K.S., Brauner, R., Papadimitriou, A., Keller, E., Keller, A., Haufs, N., Krude, H. et al. (2007) *HESX1* mutations are an uncommon cause of Septo-optic dysplasia and hypopituitarism. *J. Clin. Endocrinol. Metab.*, **92**, 691–697.
12. Tajima, T., Hattori, T., Nakajima, T., Okuhara, K., Sato, K., Abe, S., Nakae, J. and Fujieda, K. (2003) Sporadic heterozygous Frameshift mutation of *HESX1* causing pituitary and optic nerve hypoplasia and combined pituitary hormone deficiency in a Japanese patient. *J. Clin. Endocrinol. Metab.*, **88**, 45–50.
13. Thomas, P.Q. (2001) Heterozygous *HESX1* mutations associated with isolated congenital pituitary hypoplasia and septo-optic dysplasia. *Hum. Mol. Genet.*, **10**, 39–45.
14. Bosch, D.G.M., Boonstra, F.N., Gonzaga-Jauregui, C., Xu, M., de Ligt, J., Jhangiani, S., Wiszniewski, W., Muzny, D.M., Yntema, H.G., Pfundt, R. et al. (2014) *NR2F1* mutations cause optic atrophy with intellectual disability. *Am. J. Hum. Genet.*, **94**, 303–309.
15. Schilter, K., Schneider, A., Bardakjian, T., Soucy, J.-F., Tyler, R., Reis, L. and Semina, E. (2011) *OTX2* microphthalmia syndrome: four novel mutations and delineation of a phenotype. *Clin. Genet.*, **79**, 158–168.
16. Ragge, N.K., Brown, A.G., Poloschek, C.M., Lorenz, B., Henderson, R.A., Clarke, M.P., Russell-Eggitt, I., Fielder, A., Gerrelli, D., Martinez-Barbera, J.P. et al. (2005) Heterozygous mutations of *OTX2* cause severe ocular malformations. *Am. J. Hum. Genet.*, **76**, 1008–1022.
17. Slavotinek, A.M., Chao, R., Vacik, T., Yahyavi, M., Abouzeid, H., Bardakjian, T., Schneider, A., Shaw, G., Sherr, E.H., Lemke, G. et al. (2012) *VAX1* mutation associated with microphthalmia, corpus callosum agenesis, and orofacial clefting: the first description of a *VAX1* phenotype in humans. *Hum. Mutat.*, **33**, 364–368.
18. Brown, N.L., Kanekar, S., Vetter, M.L., Tucker, P.K., Gemza, D.L. and Glaser, T. (1998) *Math5* encodes a murine basic helix-loop-helix transcription factor expressed during early stages of retinal neurogenesis. *Development*, **125**, 4821–4833.
19. Wang, S.W. (2001) Requirement for *math5* in the development of retinal ganglion cells. *Genes Dev.*, **15**, 24–29.
20. Brown, N.L., Patel, S., Brzezinski, J. and Glaser, T. (2001) *Math5* is required for retinal ganglion cell and optic nerve formation. *Development*, **128**, 2497–2508.
21. Reichman, S., Slembrouck, A., Gagliardi, G., Chaffiol, A., Terray, A., Nanteau, C., Potey, A., Belle, M., Rabesandratana, O., Duebel, J. et al. (2017) Generation of storable retinal organoids and retinal pigmented epithelium from adherent human iPS cells in xeno-free and feeder-free conditions. *Stem Cells*, **35**, 1176–1188.
22. Macgregor, S., Hewitt, A.W., Hysi, P.G., Ruddle, J.B., Medland, S.E., Henders, A.K., Gordon, S.D., Andrew, T., McEvoy, B., Sanfilippo, P.G. et al. (2010) Genome-wide association identifies *ATOH7* as a major gene determining human optic disc size. *Hum. Mol. Genet.*, **19**, 2716–2724.
23. Ghasvand, N.M., Rudolph, D.D., Mashayekhi, M., Brzezinski, J.A., Goldman, D. and Glaser, T. (2011) Deletion of a remote enhancer near *ATOH7* disrupts retinal neurogenesis, causing NCRNA disease. *Nat. Neurosci.*, **14**, 578–586.
24. Keser, V., Khan, A., Siddiqui, S., Lopez, I., Ren, H., Qamar, R., Nadaf, J., Majewski, J., Chen, R. and Koenekoop, R.K. (2017) The genetic causes of nonsyndromic congenital retinal detachment: a genetic and phenotypic study of Pakistani families. *Investig. Ophthalmol. Vis. Sci.*, **58**, 1028.
25. Prasov, L., Masud, T., Khaliq, S., Mehdi, S.Q., Abid, A., Oliver, E.R., Silva, E.D., Lewanda, A., Brodsky, M.C., Borchert, M. et al. (2012) *ATOH7* mutations cause autosomal recessive persistent hyperplasia of the primary vitreous. *Hum. Mol. Genet.*, **21**, 3681–3694.
26. Khan, K., Logan, C.V., McKibbin, M., Sheridan, E., Elçioğlu, N.H., Yenice, O., Parry, D.A., Fernandez-Fuentes, N., Abdelhamed, Z.I.A., Al-Maskari, A. et al. (2012) Next generation sequencing identifies mutations in atonal homolog 7 (*ATOH7*) in families with global eye developmental defects. *Hum. Mol. Genet.*, **21**, 776–783.
27. Lim, S.-H., Germain, E.S., Tran-Viet, K.-N., Staffieri, S., Marino, M., Dollfus, P.H., Nading, E.B., Crowe, S., Gole, G., Perdomo-Trujillo, Y. et al. (2014) Sequencing analysis of the *ATOH7* gene in individuals with optic nerve hypoplasia. *Ophthalmic Genet.*, **35**, 1–6.
28. Provis, J.M. (2001) Development of the primate retinal vasculature. *Prog. Retin. Eye Res.*, **20**, 799–821.
29. Henthorn, P., McCarrick-Walmsley, R. and Kadesch, T. (1990) Sequence of the cDNA encoding ITF-1, a positive-acting transcription factor. *Nucleic Acids Res.*, **18**, 677–677.
30. Thomas, M.G., Kumar, A., Mohammad, S., Proudlock, F.A., Engle, E.C., Andrews, C., Chan, W.-M., Thomas, S. and Gotlib, I. (2011) Structural grading of foveal hypoplasia using spectral-domain optical coherence tomography. *Ophthalmology*, **118**, 1653–1660.
31. Fares-Taie, L., Gerber, S., Chassaing, N., Clayton-Smith, J., Hanein, S., Silva, E., Serey, M., Serre, V., Gérard, X., Baumann, C. et al. (2013) *ALDH1A3* mutations cause recessive anophthalmia and microphthalmia. *Am. J. Hum. Genet.*, **92**, 265–270.
32. Stevens, E., Carss, K.J., Cirak, S., Foley, A.R., Torelli, S., Willer, T., Tambunan, D.E., Yau, S., Brodd, L., Sewry, C.A. et al. (2013) Mutations in *B3GALNT2* cause congenital muscular dystrophy and hypoglycosylation of α -dystroglycan. *Am. J. Hum. Genet.*, **92**, 354–365.
33. Armour, C.M. and Allanson, J.E. (2007) Further delineation of cardio-facio-cutaneous syndrome: clinical features of 38 individuals with proven mutations. *J. Med. Genet.*, **45**, 249–254.
34. Oatts, J.T., Duncan, J.L., Hoyt, C.S., Slavotinek, A.M. and Moore, A.T. (2017) Inner retinal dystrophy in a patient with biallelic sequence variants in *BRAT1*. *Ophthalmic Genet.*, **38**, 559–561.
35. Moog, U., Bierhals, T., Brand, K., Bautsch, J., Biskup, S., Brune, T., Denecke, J., de Die-Smulders, C.E., Evers, C., Hempel, M. et al. (2015) Phenotypic and molecular insights into *CASK*-related disorders in males. *Orphanet J. Rare Dis.*, **10**, 44.
36. Schuurs-Hoeijmakers, J.H.M., Geraghty, M.T., Kamsteeg, E.-J., Ben-Salem, S., de Bot, S.T., Nijhof, B., van de Vondervoort, I.I.G.M., van der, M., Nobau, A.C., Otte-Höller, I. et al. (2012) Mutations in *DDHD2*, encoding an intracellular phospholipase A1, cause a recessive form of complex hereditary spastic paraplegia. *Am. J. Hum. Genet.*, **91**, 1073–1081.
37. Willer, T., Lee, H., Lommel, M., Yoshida-Moriguchi, T., de Bernabe, D.B.V., Venzke, D., Cirak, S., Schachter, H., Vajsar, J., Voit, T. et al. (2012) *ISPD* loss-of-function mutations disrupt dystroglycan O-mannosylation and cause Walker-Warburg syndrome. *Nat. Genet.*, **44**, 575–580.
38. Zollino, M., Marangi, G., Ponzi, E., Orteschi, D., Ricciardi, S., Lattante, S., Murolo, M., Battaglia, D., Contaldo, I., Mercuri, E. et al. (2015) Intragenic *KANSL1* mutations and chromosome

- 17q21.31 deletions: broadening the clinical spectrum and genotype-phenotype correlations in a large cohort of patients. *J. Med. Genet.*, **52**, 804–814.
39. Raffa, L., Matton, M.-P., Michaud, J., Rossignol, E., Decarie, J.-C. and Ospina, L.H. (2017) Optic nerve hypoplasia in a patient with a de novo KIF1A heterozygous mutation. *Can. J. Ophthalmol.*, **52**, e169–e171.
 40. Azuma, N., Nishina, S., Yanagisawa, H., Okuyama, T. and Yamada, M. (1996) PAX6 missense mutation in isolated foveal hypoplasia. *Nat. Genet.*, **13**, 141–142.
 41. El Chehadeh, S., Kerstjens-Frederikse, W.S., Thevenon, J., Kuentz, P., Bruel, A.-L., Thauvin-Robinet, C., Bensignor, C., Dollfus, H., Laugel, V., Rivière, J.-B. et al. (2017) Dominant variants in the splicing factor PUF60 cause a recognizable syndrome with intellectual disability, heart defects and short stature. *Eur. J. Hum. Genet.*, **25**, 43–51.
 42. Lamers, I.J.C., Reijnders, M.R.F., Venselaar, H., Kraus, A., Jansen, S., de Vries, B.B.A., Houge, G., Gradek, G.A., Seo, J., Choi, M. et al. (2017) Recurrent de novo mutations disturbing the GTP/GDP binding pocket of RAB11B cause intellectual disability and a distinctive brain phenotype. *Am. J. Hum. Genet.*, **101**, 824–832.
 43. Ullah, E., Wu, D., Madireddy, L., Lao, R., Ling-Fung Tang, P., Wan, E., Bardakjian, T., Kopinsky, S., Kwok, P.-Y., Schneider, A. et al. (2017) Two missense mutations in SALL4 in a patient with microphthalmia, coloboma, and optic nerve hypoplasia. *Ophthalmic Genet.*, **38**, 371–375.
 44. Reyes-Capó, D.P., Chen, F., Wilson, B., Tarshish, B., Ventura, C.V., Read, S.P., Negron, C.I. and Berrocal, A.M. (2018) Aggressive posterior retinopathy of prematurity and a TUBA1A mutation inde Morsier syndrome. *Ophthalmic Surg Lasers Imaging Retin.*, **49**, 629–632.
 45. Abdollahi, M.R., Morrison, E., Sirey, T., Molnar, Z., Hayward, B.E., Carr, I.M., Springell, K., Woods, C.G., Ahmed, M., Hattingh, L. et al. (2009) Mutation of the variant α -tubulin TUBA8 results in Polymicrogyria with optic nerve hypoplasia. *Am. J. Hum. Genet.*, **85**, 737–744.
 46. Ejaz, R., Lionel, A.C., Blaser, S., Walker, S., Scherer, S.W., Babul-Hirji, R., Marshall, C.R., Stavropoulos, D.J. and Chitayat, D. (2017) De novo pathogenic variant in TUBB2A presenting with arthrogryposis multiplex congenita, brain abnormalities, and severe developmental delay. *Am. J. Med. Genet. A*, **173**, 2725–2730.
 47. Kohl, S., Zobor, D., Chiang, W., Weisschuh, N., Staller, J., Menendez, I.G., Chang, S., Beck, S.C., Garrido, M.G., Sothilingam, V. et al. (2015) Mutations in the unfolded protein response regulator ATF6 cause the cone dysfunction disorder achromatopsia. *Nat. Genet.*, **47**, 757–765.
 48. Thiadens, A.A.H.J., Somervuo, V., van den Born, L.I., Roosing, S., van Schooneveld, M.J., Kuijpers, R.W.A.M., van Moll-Ramirez, N., Cremers, F.P.M., Hoyng, C.B. and Klaver, C.C.W. (2010) Progressive loss of cones in achromatopsia: an imaging study using spectral-domain optical coherence tomography. *Investig. Ophthalmol. Vis. Sci.*, **51**, 5952.
 49. Liu, J.Y., Ren, X., Yang, X., Guo, T., Yao, Q., Li, L., Dai, X., Zhang, M., Wang, L., Liu, M. et al. (2007) Identification of a novel GPR143 mutation in a large Chinese family with congenital nystagmus as the most prominent and consistent manifestation. *J. Hum. Genet.*, **52**, 565–570.
 50. Murro, V., Mucciolo, D.P., Sodi, A., Passerini, I., Giorgio, D., Virgili, G. and Rizzo, S. (2019) Novel clinical findings in autosomal recessive NR2E3-related retinal dystrophy. *Graefes Arch. Clin. Exp. Ophthalmol.*, **257**, 9–22.
 51. Perez, Y., Gradstein, L., Flusser, H., Markus, B., Cohen, I., Langer, Y., Marcus, M., Lifshitz, T., Kadir, R. and Birk, O.S. (2014) Isolated foveal hypoplasia with secondary nystagmus and low vision is associated with a homozygous SLC38A8 mutation. *Eur. J. Hum. Genet.*, **22**, 703–706.
 52. Dennis, D.J., Han, S. and Schuurmans, C. (2019) bHLH transcription factors in neural development, disease, and reprogramming. *Brain Res.*, **1705**, 48–65.
 53. Longo, A., Guanga, G.P. and Rose, R.B. (2008) Crystal structure of E47-NeuroD1/Beta2 bHLH domain–DNA complex: heterodimer selectivity and DNA recognition. *Biochemistry*, **47**, 218–229.
 54. Voronova, A. and Baltimore, D. (1990) Mutations that disrupt DNA binding and dimer formation in the E47 helix-loop-helix protein map to distinct domains. *Proc. Natl. Acad. Sci.*, **87**, 4722–4726.
 55. Nie, L. (2003) Notch-induced E2A ubiquitination and degradation are controlled by MAP kinase activities. *EMBO J.*, **22**, 5780–5792.
 56. Sallee, M.D. and Greenwald, I. (2015) Dimerization-driven degradation of *C. elegans* and human E proteins. *Genes Dev.*, **29**, 1356–1361.
 57. Bounpheng, M.A., Dimas, J.J., Dodds, S.G. and Christy, B.A. (1999) Degradation of Id proteins by the ubiquitin-proteasome pathway. *FASEB J.*, **13**, 2257–2264.
 58. Pacal, M. and Bremner, R. (2014) Induction of the ganglion cell differentiation program in human retinal progenitors before cell cycle exit. *Dev. Dyn.*, **243**, 712–729.
 59. Sızmad, S., Yonekawa, Y. and Trese, M.T. (2015) Familial exudative vitreoretinopathy. *Türk Oftalmol. Derg.*, **45**, 164–168.
 60. Ben Ezra, R., Davis, R.L., Lockshon, D., Turner, D.L. and Weintraub, H. (1990) The protein Id: a negative regulator of helix-loop-helix DNA binding proteins. *Cell*, **61**, 49–59.
 61. Duke-Elder, S. (1963) *System of Ophthalmology*. The C.V. Mosby Company, St. Louis, MO.
 62. Kondo, H. (2018) Foveal hypoplasia and optical coherence tomographic imaging. *Taiwan J. Ophthalmol.*, **8**, 181.
 63. Querques, G., Prascina, F., Iaculli, C. and Noci, N.D. (2009) Isolated foveal hypoplasia. *Int. Ophthalmol.*, **29**, 271–274.
 64. Giocanti-Aurégan, A., Witmer, M.T., Radcliffe, N.M. and D'Amico, D.J. (2014) Isolated foveal hypoplasia without nystagmus. *Int. Ophthalmol.*, **34**, 877–880.
 65. Kirchner, I.D., Waldman, C.W. and Sunness, J.S. (2019) A series of five patients with foveal hypoplasia demonstrating good visual acuity. *Retin. Cases Brief Rep.*, **13**, 376–380.
 66. Curran, R.E. and Robb, R.M. (1976) Isolated foveal hypoplasia. *Arch. Ophthalmol.*, **94**, 48–50.
 67. O'Donnell, F.E. (1982) Autosomal dominant foveal hypoplasia and presenile cataracts. *Arch. Ophthalmol.*, **100**, 279.
 68. Al-Araimi, M., Pal, B., Poulter, J.A., van Genderen, M.M., Carr, I., Cudrnak, T., Brown, L., Sheridan, E., Mohamed, M.D., Bradbury, J. et al. (2013) A new recessively inherited disorder composed of foveal hypoplasia, optic nerve decussation defects and anterior segment dysgenesis maps to chromosome 16q23.3-24.1. *Mol. Vis.*, **19**, 2165–2172.
 69. Pilat, A., Sibley, D., McLean, R.J., Proudlock, F.A. and Gottlob, I. (2015) High-resolution imaging of the optic nerve and retina in optic nerve hypoplasia. *Ophthalmology*, **122**, 1330–1339.
 70. Huizing, M., Dorward, H., Ly, L., Klootwijk, E., Kleta, R., Skovby, F., Pei, W., Feldman, B., Gahl, W.A. and Anikster, Y. (2010) OPA3, mutated in 3-methylglutaconic aciduria type III, encodes two transcripts targeted primarily to mitochondria. *Mol. Genet. Metab.*, **100**, 149–154.

71. Ryu, S.-W., Jeong, H.J., Choi, M., Karbowski, M. and Choi, C. (2010) Optic atrophy 3 as a protein of the mitochondrial outer membrane induces mitochondrial fragmentation. *Cell. Mol. Life Sci.*, **67**, 2839–2850.
72. Wells, T., Davies, J.R., Guschina, I.A., Ball, D.J., Davies, J.S., Davies, V.J., Evans, B.A.J. and Votruba, M. (2012) Opa3, a novel regulator of mitochondrial function, controls thermogenesis and abdominal fat mass in a mouse model for Costeff syndrome. *Hum. Mol. Genet.*, **21**, 4836–4844.
73. Powell, K.A., Davies, J.R., Taylor, E., Wride, M.A. and Votruba, M. (2011) Mitochondrial localization and ocular expression of mutant Opa3 in a mouse model of 3-methylglutaconicaciduria type III. *Investig. Ophthalmol. Vis. Sci.*, **52**, 4369.
74. Anikster, Y., Kleta, R., Shaag, A., Gahl, W.A. and Elpeleg, O. (2001) Type III 3-methylglutaconic aciduria (optic atrophy plus syndrome, or Costeff optic atrophy syndrome): identification of the OPA3 gene and its founder mutation in Iraqi Jews. *Am. J. Hum. Genet.*, **69**, 1218–1224.
75. Reynier, P. (2004) OPA3 gene mutations responsible for autosomal dominant optic atrophy and cataract. *J. Med. Genet.*, **41**, e110–e110.
76. Lenaers, G., Hamel, C.P., Delettre, C., Amati-Bonneau, P., Procaccio, V., Bonneau, D., Reynier, P. and Milea, D. (2012) Dominant optic atrophy. *Orphanet J. Rare Dis.*, **7**, 46.
77. Tewarie, P., Balk, L., Costello, F., Green, A., Martin, R., Schippling, S. and Petzold, A. (2012) The OSCAR-IB consensus criteria for retinal OCT quality assessment. *PLoS One*, **7**, e34823.
78. Cruz-Herranz, A., Balk, L.J., Oberwahrenbrock, T., Saidha, S., Martinez-Lapiscina, E.H., Lagreze, W.A., Schuman, J.S., Villoslada, P., Calabresi, P., Balcer, L. et al. (2016) The APOSTEL recommendations for reporting quantitative optical coherence tomography studies. *Neurology*, **86**, 2303–2309.
79. Robinson, J.T., Thorvaldsdóttir, H., Winckler, W., Guttman, M., Lander, E.S., Getz, G. and Mesirov, J.P. (2011) Integrative Genomics Viewer. *Nat. Biotechnol.*, **29**, 24–26.
80. Tiwari, A., Bahr, A., Bähr, L., Fleischhauer, J., Zinkernagel, M.S., Winkler, N., Barthelmes, D., Berger, L., Gerth-Kahlert, C., Neidhardt, J. et al. (2016) Next generation sequencing based identification of disease-associated mutations in Swiss patients with retinal dystrophies. *Sci. Rep.*, **6**, 28755.